Acasti Pharma Inc. ACST
Day range unavailable
52-week range unavailable
- Market cap
- 34.17M
- Shares out
- 10.14M
- Forward P/E
- -2.67
- Beta
- 1.52
- Analysts
- Buy
- Price target
- 7.97 (+136.5%)
- Earnings date
- Nov 11, 2024
Key statistics
- Enterprise value
- 13.14M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.58M
- Total cash
- 19.41M
- Total debt
- 0
- Return on equity
- -18.56%
- Short % of float
- 1.93%
- 50-day average
- 3.05
- 200-day average
- 2.99
Analyst view
Consensus: buy
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 11, 2024
Expected Nov 11, 2024. Consensus EPS estimate -0.46.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.34 | — | — | — |
| Aug 9, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| Jun 21, 2024 | Mar 1, 2024 | -0.35 | — | — | — |
| Feb 12, 2024 | Dec 1, 2023 | -0.30 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.29 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -0.63 | — | — | — |
About Acasti Pharma Inc.
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acastipharma.com
News
ACS Technologies and the Evangelical Lutheran Church in America Expand Strategic Partnership to Deliver a Connected Ministry Experience 
Vanco, ACS Technologies, and GCFA Strengthen Partnership Through Expanded Ministry Ecosystem 
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. 
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104 
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update 
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? 
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial 
Acasti Announces Year-End 2024 Financial Results, Provides Business Update 
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
Your note
Sign in to keep a note on ACST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Kohli (Prashant) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Sep 8, 2022 | 128,138 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Adar1 Capital Management, LLC | 0.00% | 959,571 | 3.23M | Jun 29, 2024 |
| AIGH Capital Management LLC | 0.00% | 641,083 | 2.16M | Jun 29, 2024 |
| Bank of America Corporation | 0.00% | 494,698 | 1.67M | Jun 29, 2024 |
| Susquehanna International Group, LLP | 0.00% | 37,793 | 127.36K | Jun 29, 2024 |
| Royal Bank of Canada | 0.00% | 6,584 | 22.19K | Jun 29, 2024 |
| National Bank of Canada/FI | 0.00% | 2,901 | 9.78K | Jun 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 3,058 | 10.30K | Aug 30, 2024 |
| Series Portfolios Tr-Unusual Whales Subversive Republican Trading ETF | 0.00% | 309 | 1.04K | Jun 29, 2024 |